Form 4: Apyx Medical Corp Director Acquires Stock Options

Lawrence Waldman, a director at Apyx Medical Corp, was granted stock options to purchase 30,000 shares of common stock.

Summary

• On May 15, 2025, Lawrence Waldman, a director of Apyx Medical Corp, was granted stock options.
• The options allow him to purchase 30,000 shares of Apyx Medical Corp common stock at an exercise price of $1.48 per share.
• The options vest ratably over a 12-month period, becoming fully vested and exercisable on the first anniversary of the grant date.
• The options expire on May 15, 2035.

Sentiment

Score: 6

Explanation: The document indicates a standard grant of stock options to a director, which is generally a neutral event. It suggests confidence in the company's future, but doesn't provide any groundbreaking news.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock options are a common form of executive compensation in the medical device industry, aligning management's interests with shareholder value.

Stakeholder Impact

• The granting of stock options can have a positive impact on shareholders by aligning the interests of the director with the company's long-term success.

Key Dates

Keywords

stock options, director, Apyx Medical Corp, beneficial ownership, Form 4, Waldman, equity